New radioactive tracer could sharpen cancer detection
NCT ID NCT06471712
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This early-phase trial tested a new radioactive imaging agent called 18F-LNC1007 in 8 people: healthy volunteers and cancer patients with small tumors. The goal was to see how the agent spreads through the body, how much radiation it gives off, and whether it is safe. Participants received a single injection and underwent PET/CT scans over several hours.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Precision Molecular Imaging & Theranostics (trading as Melbourne Theranostic Innovation Centre)
Melbourne, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-LNC1007 injection (a radioactive imaging agent)
What this could lead to
If successful, this could lead to a new imaging method to better detect and monitor small tumors.
What could go wrong
This is a very early, small trial (8 people) focused on safety and imaging properties, not treatment. It may not lead to a widely used diagnostic tool.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.